Last reviewed · How we verify
NCT05264558
Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30%
Phase 4 trial testing Xpert HCV Viral load finger stick point of care test (Cepheid) in Hepatitis C in 606 participants. Completed in 30 September 2023.
31 August 2023
Quick facts
| Lead sponsor | Macfarlane Burnet Institute for Medical Research and Public Health Ltd |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 606 |
| Start date | 25 July 2022 |
| Primary completion | 31 August 2023 |
| Estimated completion | 30 September 2023 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Xpert HCV Viral load finger stick point of care test (Cepheid)
- Epclusa 400Mg-100Mg Tablet — full drug profile →
- Standard of care
Conditions studied
- Hepatitis C — all drugs for Hepatitis C →
Sponsor
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Who can join
18 and older, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to assess the impact of models of HCV care on HCV testing, treatment uptake and cure within Cairns. Point of care testing for HCV , with test and treat strategies will be offered within a primary care service.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05264558
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatitis C
Currently open trials in the same condition.
- NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
- NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
- NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
- NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
- NCT05208697 — Tele-Harm Reduction · NA · active not recruiting
Other Macfarlane Burnet Institute for Medical Research and Public Health Ltd trials
Trials by the same sponsor.
- NCT05874271 — Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea · NA · completed
- NCT07337382 — The Optimising Isolation, Quarantine and Distancing Study for COVID-19 · active not recruiting
- NCT05323799 — The Optimising Isolation, Quarantine and Distancing Study for COVID-19 (Optimise) · unknown
- NCT04510246 — Link Hepatitis C Notifications to Treatment in Tasmania · NA · unknown
- NCT03939013 — Hepatitis C: Community Testing and Treatment (CT2 Study Myanmar) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05264558 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Macfarlane Burnet Institute for Medical Research and Public Health Ltd
- Last refreshed: 13 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05264558.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing